Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease;; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use.

testing of computer programs; computer software development; testing of computers; software engineering; testing of computer installations; development of computer software application solutions; computer software engineering; development of computer software; maintenance of computer software; computer software consultancy; installation of computer software; technical diagnostic testing services; computer software design; technical testing services; testing of computing equipment; development of software; updating of computer software; installation of middleware (software); design of computer software; computer software advisory services; computer security services (testing and risk assessment of computer networks); installation and maintenance of computer software; information technology (it) services (computer hardware, software and peripherals design and technical consultancy); software development in the framework of software publishing; repair of computer software; scientific testing services; development of testing methods; software creation

Pharmaceutical preparations and substances for the treatment of osteoporosis; pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; pharmaceutical preparations and substances for the treatment of cartilage disorders; pharmaceutical preparations and substances for the treatment of bone disorders; pharmaceutical preparations and substances for the treatment of bone loss; pharmaceutical preparations and substances for the alleviation of bone-loss related symptoms; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures; pharmaceutical preparations and substances for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture; pharmaceutical preparations for the treatment of menopause; pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; pharmaceutical preparations and substances for use in relation to women’s health; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for the treatment of arthritis; pharmaceutical preparations and substances for the treatment of rheumatoid arthritis; pharmaceutical preparations and substances for the treatment of juvenile idiopathic polyarthritis; pharmaceutical preparations and substances for the treatment of active systemic juvenile idiopathic arthritis; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in the treatment of respiratory conditions; pharmaceutical preparations and substances for use in the treatment of coronavirus disease;; pharmaceutical preparations and substances for use in the treatment of cytokine release syndrome; all the above being for human use.